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Abstract 
Aims: There is a paucity of robust evidence on the prevention and management of diabetic foot 
ulcers (DFU’s) to inform treatment. This study appraises the current quality of the evidence 
addressing the diagnosis, prognosis and management of peripheral artery disease (PAD) in patients 
with DFU’s using a newly devised 21-point (TOP) disease-specific research appraisal tool published 
by the International Working Group on the Diabetic Foot (IWGDF) and European Wound 
Management Association. 
Methods: The 2015 IWGDF guidance on diagnosis, prognosis, and management of PAD in patients 
with DFU’s was used to identify studies pertaining to prevention and management. Two reviewers 
assessed these articles against the TOP checklist which examines study design, conduct and outcome 
reporting.  
Results: Overall median score was 8 (3-12) out of 21. Median design total score was 2 (0-4) out of 11. 
Median conduct total score was 2(1-4) out of 6. Median outcomes total score was 3 (1-4) out of 4. 
There was improvement with time in overall total (Spearman Rho 0.39, p=0.0005), design total (0.35, 
p=0.0023), outcomes total (0.35, p=0.0002) but not conduct total (-0.03, p=0.8132) scores.  
Conclusions: Whilst this analysis revealed an improvement over time in the overall calibre of studies, 
the present quality remains poor.  
 
 
  
Introduction 
The International Diabetes Federation project that the global prevalence of diabetes mellitus is set 
to rise to approximately 600 million by 2035.1 Foot ulcers complicating diabetes are burdensome for 
patients and costly for society. There is a paucity of robust evidence on the prevention and 
management of diabetic foot ulcers (DFU’s) to inform treatment, leading to calls for higher quality 
research from recently published systematic reviews.2, 3, 4, 5, 6, 7  As a consequence Jeffcoate et al. 
2016 produced a 21-point (TOP) checklist on behalf of the International Working Group on the 
Diabetic Foot (IWGDF) and the European Wound Management Association (EWMA) both 
highlighting and addressing the shortcomings of existing appraisal methodologies. This checklist 
integrates the exigencies of diabetic foot reporting standards into a single disease specific research 
appraisal tool.8 TOP summarises details that should be included in study design, conduct, and 
reporting for publications addressing prevention and management of DFU’s. The ultimate goal is of 
course that the research community will adopt the specified criteria into future reports to improve 
reporting standards. To date no study has examined the utility or validity of the TOP checklist in 
assessing the current quality of published work on DFU’s. 
The aim of this study was to appraise the current quality of the evidence addressing the diagnosis, 
prognosis and management of peripheral artery disease (PAD) in patients with DFU’s using the TOP 
checklist. The IWGDF has been publishing and updating international guidelines on the prevention 
and management of foot problems in diabetes since 1999 based upon best available evidence. We 
decided to use IWGDF guidance as a source of original research to examine the current quality of 
reporting standards in the diabetic foot ulcer literature. 
Methodology  
We utilised the 2015 IWGDF guidance on diagnosis, prognosis, and management of PAD in patients 
with foot ulcers in diabetes to identify studies pertaining to the prevention and management of 
DFU.10 Within this document are cited three systematic reviews that summarise the literature, all 
conforming to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidance.11 Using the studies cited by Hinchliffe et al. 2016 (n = 57), Brownrigg et al. 2016 (n = 10) 
and Brownrigg et al.  2016 (n = 11) we identified  a total of 78 original research articles to be 
assessed in our study.4, 12, 13  We categorised studies into case series, cross-sectional studies, cohort 
studies and randomised trials. 
We used the TOP scoring system to assess the quality of published work cited within the systematic 
reviews. Three broad areas of study design, study conduct and outcome reporting were assessed 
according to this checklist with a maximum score of 11, 6 and 4 respectively. For non-randomised 
studies it was not possible to score in some domains of the TOP checklist by virtue of the deficiencies 
in their design.  
Scoring was performed by two independent assessors (S.R.A. and B.A.O.). When conflict did arise a 
third, senior author (R.J.H.) was consulted and an agreement reached. Descriptive data analysis was 
performed using Microsoft Excel 2010® (Microsoft Cooperation, Redmond, Washington USA) and 
statistical analysis performed using R 3.1.1 (R Core Team, R Foundation for Statistical Computing, 
Vienna, Austria). 
Medians are reported alongside range. The change in score by year of publication was tested using 
Spearman’s rank correlation coefficient, which is a non-parametric measure of rank correlation, and 
p < 0.05 was considered statistically significant.  
Results 
The most common study design was case series (n = 54), followed by cohort study (n = 19) and cross-
sectional study (n = 5). There were no randomised trials. 
The overall (total) median score was 8 (3-12) out of 21. The median design total score was 2 (0-4) 
out of 11.The median conduct total score was 2(1-4) out of 6. The median outcomes total score was 
3 (1-4) out of 4. 
Over the period of the analysis there was improvement with time in the overall total (Spearman Rho 
0.39, p=0.0005), design total (0.35, p =0.0023), outcomes total (0.35, p=0.0002) but not the conduct 
total (-0.03, p=0.8132) scores. Figure 1 demonstrates however that the improvements for the overall 
and design total though statistically significant hide the fact that the overall quality of studies 
remains poor. 
Table 1 lists and summarises the results for each item in the TOP scoring system. With regards to 
items addressing study design, only 21% of studies used appropriate definitions for “ulcer”, 
“healing”, and all other aspects of the population studied and their outcomes. The quality of 
reporting for this item did improve over the course of the study (Spearman Rho 0.35, p=0.0015). 
Only 17% of studies chose a primary outcome of direct clinical relevance. No studied randomised or 
blinded the researchers, clinicians or participants. Only one study performed an appropriate sample 
size calculation.14  
15% of studies documented the primary outcome in 75% or more of participants whilst 5% analysed 
the results primarily by intention to treat analysis. 
The reporting of outcomes was judged to be more robust except that only 51% of studies discussed 
the important strengths and weaknesses of the study, though this did improve over the course of 
the analysis (Spearman Rho 0.44, p>0.0001). 
Except for the two items already highlighted no other individual item demonstrated a significant 
improvement over the course of the analysis. 
 
Discussion 
Improvement with time 
There has been modest improvement with time in the reporting of study design and outcomes, 
leading to improvements in the overall total TOPS score. The improvements in study design reflect 
moderate improvements in the use of appropriate definitions for key aspects of the population and 
outcome as well as for the detail with which studies were described. The improvements in study 
outcome reporting largely reflect an improvement in the description of study strengths and 
weaknesses over time. These improvements may reflect the introduction of guidelines for reporting 
observational studies such as STROBE.15 It must be emphasised that the reporting for the majority of 
items listed in TOPS did not improve over time. This probably reflects a failure of authors to 
accommodate the multifactorial aetiology of foot ulceration in patients with diabetes, nor their 
multidisciplinary management. 
Overall poor quality 
Whilst this analysis revealed an improvement over time in the overall calibre of studies addressing 
the diagnosis, prognostication and revascularisation of patients with diabetes and PAD, the present 
quality remains poor. This is particularly true for the design and conduct of studies. This is 
attributable to a number of factors which we discuss here. 
Poor quality of design and conduct 
Studies to date have failed to address the issue of heterogeneity of patients with DFU’s. It is very 
difficult from the present literature to ascertain the impact of current management strategies as 
very few studies have used appropriate definitions of ulcer and PAD severity or healing.16-31 Future 
analysis will need to stratify patients by severity and use more robust measures of outcome to 
improve the external validity of studies.  
Interventions as part of PAD management in patients with DFU’s are inevitably given in conjunction 
with other components of care such as ulcer offloading footwear, dressings, antimicrobials and 
pharmacological regimes. These vital components need to be accounted for in trial design and to be 
adequately described for external validity and to facilitate critical appraisal of comparative data.  A 
common observation throughout the analysis was that very few authors reported these other 
components of care.16, 18, 19, 23, 25, 26, 32-42  
It is common research practise to define primary outcome at the time of study design to reduce the 
risk of type I error resulting from the statistical testing of many outcomes and type II error by 
providing the basis for a sample size calculation and an adequately powered study. Primary outcome 
measures were infrequently documented in the studies examined, compromising the internal 
validity of and the conclusions which can be gleaned from these reports.14, 17, 20-22, 34, 43-49 
Given that there were no randomised studies included in the analysis, features of this specific trial 
design (control group, independent randomisation, blinding and control group performance), that 
account for 19% of the total TOPS checklist as markers of good quality, could not be awarded in any 
case. The paucity of these hallmarks of trial quality highlight the overall need for RCT‘s in the DFU 
literature.  
Diagnosis 
Non-invasive tests for the detection of PAD among individuals with diabetes help to estimate the risk 
of amputation, ulceration, wound healing and the presence of cardiovascular disease. Despite this 
rationale, there is no evidence to support a single non-invasive diagnostic test for PAD detection 
across the spectrum of patients with diabetes.4 Diagnostic performance varies according to 
populations studied and a poor description of these cohorts in the literature limits the applicability 
of any ﬁndings to a particular patient group.4 Standardized reporting would establish comparative 
datasets to identify which test(s) can best identify PAD assisting in diagnosis, prognostication and 
management of diabetic foot complications and cardiovascular risk. 
Screening tests for PAD can help to identify patients at higher risk of ulceration and most 
importantly those at greater risk of amputation when tissue loss is already established.4 Particularly 
in this latter group the majority of the literature again fails to stratify patients according to disease 
severity (neuropathy, ulcer classification etc.) and therefore the differential utility of each test in the 
various strata is unclear.42, 50-56 
Prognostication  
There is a consensus that PAD is associated with poor outcome in DFU, however the exact PAD 
characteristics which correlate with a poor outcome is unknown.12 PAD is variable in its distribution 
and severity with a tendency of diabetic patients to have diffuse and distal disease with a greater 
prevalence of medial sclerosis and poor collateral formation. We need to address the clinically 
important questions of whether it is possible to identify speciﬁc characteristics of PAD that predict a 
poor outcome, at which point in the disease natural history is revascularization is needed to prevent 
a poor outcome, or whether there is a group of patients in whom a poor outcome is likely regardless 
of revascularization. In the current analysis of prognostic studies only six studies included 
appropriate definitions for the terms “ulcer”, “healing” and all other required aspects of the 
population and the outcomes.24-29 The development of a registry to standardize data collection 
addressing the poor quality of evidence currently available, would help to determine which 
demographic, comorbidity, ulcer-related and PAD factors predict failure to heal. Standardisation of 
data collection and reporting would allow comparisons of practice and outcome across research 
sites to maximizing precision, whilst accounting for heterogeneity and allowing adjusted for 
potential confounding factors.  
Treatment 
Much of the literature focuses on procedure specific (technical success, re-stenosis, target lesion 
revascularisation) instead of disease specific (wound healing, major amputation) or clinical 
(amputation free survival) outcome measures. Specifically only 17% of studies defined a primary 
outcome of direct clinical relevance. Future study designs should address this discrepancy and 
ensure that appropriately sized studies powered to detect clinically relevant differences are 
undertaken.  
There are no studies addressing the effectiveness of revascularisation versus best medical and 
wound therapy alone in patients with diabetes related foot ulceration. Whilst it is unlikely such a 
trial would ever be conducted more robust stratification of patients in observational studies could 
allow a comparison of successfully and unsuccessfully revascularised patients according to disease 
severity. Randomised trials comparing the various revascularisation strategies are warranted and it is 
important that these are conducted on or robust sub-group analysis performed in patients with 
diabetes. 
Limitations 
We acknowledge that the creation of the TOPS checklist was based upon expert opinion from IWGDF 
members. Delphi consensus would have been the gold standard methodology to produce a 
recognised validated appraisal tool. There is very little robust methodology in the vascular surgery 
literature that considers validating disease specific appraisal tools and none specifically centred on 
reporting standards. However, Delphi consensus methodology has been successfully used to develop 
and adopt a core outcome sets for use in colorectal cancer surgical trials and research and also audit 
studies in reconstructive breast surgery.57, 58 
We selected the evidence addressing the diagnosis, prognosis and management of PAD in patients 
DFU’s as a surrogate of the overall quality of reporting standards in the DFU literature. We recognise 
that including all of the IWGDF group’s systematic reviews would have comprehensively appraised 
the entirety of the DFU literature to provide an analysis representative of the other preventative and 
treatment modalities.  
Conclusion 
This study appraised the quality of reporting in the literature surrounding the diagnosis, prognosis 
and management of PAD in patients with DFU’s using the TOP checklist. Future work should focus on 
validating the TOP checklist not only for its use in PAD but also for studies examining prevention of 
foot ulcers in at-risk patients, footwear and offloading to prevent and heal foot ulcers, diagnosis and 
management of foot infections in persons with diabetes as well as interventions to enhance healing 
of chronic DFU’s. The TOP checklist focuses on reporting standards and incorporates aspects on 
outcome reporting as markers of good quality. Ultimately, the DFU research community should 
aspire to achieve a core outcome dataset as described by our colleagues in colorectal and breast 
reconstruction surgery. Only then would we be able to truly compare results from individual studies 
having diminished the marked heterogeneity in reporting observed in this analysis. The ultimate aim 
is to be able to stratify the DFU patient population in such a way as to be able to select and target 
treatments to the most appropriate subgroup.   
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Table 1: List and summary of results for each item in the TOPS checklist.  Change in score by year of publication tested using Spearman’s rank correlation coefficient. 
    Median 
Percentage 
scoring (n) 
Spearman 
Rho P value 
Study 
Design 
Are appropriate definitions included for the terms “ulcer”, “healing”, and all other required aspects 
of the population and the outcomes 
  
21 (16) 0.35 0.0015 
Was the choice of study population appropriate for the chosen intervention and the stated 
conclusions?   
  
94 (73) 0.03 0.8079 
Was there a control population that was managed at the same time as those in the intervention 
group or groups?   
  
3 (2) -0.05 0.6716 
Is the intervention sufficiently well described to enable another researcher to replicate the study?   79 (62) 0.2 0.0778 
Are the components of other aspects described for the intervention and comparator groups?     21 (16) 0.16 0.1552 
Were the participants randomised into intervention and comparator groups?     0 NA NA 
Were the participants randomised by an independent person or agency?     0 NA NA 
Was the number of participants studied in the trial based on an appropriate sample size calculation? 
  
  
1 (1) 0.04 0.7077 
Was the chosen primary outcome of direct clinical relevance?     17 (13) 0.17 0.1402 
Was the person who assessed the primary outcome or outcomes blinded to group  allocation?     0 NA NA 
Were either the clinical researcher who cared for the wound at research visits or the participants 
blinded to group allocation?   
  
0 NA NA 
Design Total Score 2   0.34 0.0023 
Study 
Conduct 
Did the study complete recruitment?     1 (1) 0.04 0.7077 
Was it possible to document the primary outcome in 75% or more of those recruited?     15 (12) 0.05 0.6748 
Were the results analysed primarily by ITT analysis?     6 (5) -0.03 0.7923 
Were appropriate statistical methods used throughout?     94 (73) -0.03 0.7923 
Was the performance in the control group of the order that would be expected in routine clinical 
practice?   
  
0 NA NA 
Are the results from all participating centres comparable? Answer “yes” if the study was done in only 
one centre. 
  
92 (72) -0.06 0.5761 
Conduct Total 2   -0.03 0.8132 
Outcomes 
Is the report free from errors of reporting - e.g., discrepancies between data reported in different 
parts of the report?   
  
95 (74) 0.09 0.4369 
Are the important strengths and weaknesses of the study discussed in a balanced way?     51 (40) 0.44 >0.001 
Are the conclusions supported by the findings?     78 (61) 0.07 0.555 
Is the report free from any suggestion that the analysis or the conclusions could have  been 
substantially influenced by people with commercial or other personal interests in the findings?   
  
96 (75) 0.11 0.319 
Outcomes Total 3   0.35 0.0020 
Overall Total Score 8   0.39 0.0004764 
 
  
Figure 1: Temporal relationship of TOP checklist score and year of publication of research articles appraised in the study. Separate graphs for overall TOP score and 
breakdown by checklist item domain into design, conduct and outcome.  
 
 
  
Supplementary Appendix  
Appendix 1: Raw data 
Domains Checklist Question Aboyans 2008 54 Acin 2014 21 AhChong 2004 58 Alexandrescu 2009 15  Alexandrescu 2011 39 Apelqvist 2011 59 Bargellini 2008 42 Brechow 2009 26  Bunt 1980 25 Clairotte 2009 29 Davidson 1993 61 Dorweiler 2002 32 Dosluoglu 2008 31  Elgzyri 2013 24 Elgzyri 2014 23 Ezio 2010 30 
 
                  
 
 Are appropriate definitions included for the terms “ulcer”, “heali 0 1 0 1 0 0 0 1 1 1 0 0 0 1 1 1 
 
                   
 Was the choice of study population appropriate for the chosen 
1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1   intervention and the stated conclusions?    
                  
 Was there a control population that was managed at the same 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   time as those in the intervention group or groups?    
                  
 Is the intervention sufficiently well described to enable another 
1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1   
researcher to replicate the stdy?  
                  
 Are the components of other aspects described for the 0 0 0 1 1 0 0 1 0 0 0 1 1 0 0 0   intervention and comparator groups?     
                  
Study Design Were the participants randomised into intervention and 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
comparator groups?    
                  
 Were the participants randomised by an independent person or 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   agency?    
                  
 Was the number of participants studied in the trial based on an 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   appropriate sample size calculation?    
                  
 Was the chosen primary outcome of direct clinical relevance?   0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
 
                  
 
 Was the person who assessed the primary outcome or 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   
outcomes blinded to group  allocation?                     
 
 Were either the clinical researcher who cared for the wound at 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   research visits or the participants blinded to group allocation?    
                  
 Did the study complete recruitment?   0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 
                   
 Was it possible to document the primary outcome in 75% or 
0 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0   more of those recruited?    
                  
Study Conduct Were the results analysed primarily by ITT analysis?   0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0                    
Were appropriate statistical methods used throughout?   1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1   
 
                   
 Was the performance in the control group of the order that 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   would be expected in routine clinical practice?    
                  
 Are the results from all participating centres comparable? 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1   Answer “yes” if the study was done in only one centre.                   
 
 Is the report free from errors of reporting - e.g., discrepancies 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1   between data reported in different parts of the report?    
                  
 Are the important strengths and weaknesses of the study 1 1 0 1 1 1 0 1 0 0 0 0 1 1 1 0   
discussed in a balanced way?                     
 
Outcomes Are the conclusions supported by the findings?   1 0 1 0 1 1 0 1 1 1 1 1 1 1 1 1 
 
                   
 Is the report free from any suggestion that the analysis or the                 
 
 conclusions could have  been substantially influenced by 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1   
people with commercial or other personal interests in the                   
 
 findings?                   
 
 Study Design Cohort study Case series Case series Case series Cohort study Cohort study Case series Cohort study Cohort study Cohort study Case series Case series Case series Cohort study Cohort study Cohort study 
 
                  
 
 Total Score (/21) 8 8 7 10 8 8 9 10 8 7 8 8 9 9 9 8 
 
                  
 
 
  
Domains Checklist Question Faglia 2002 16 Faglia 2005 17 Faglia 2009 18 Faris 1985 62 Ferraresi 2008 33 Gargiulo 2008 19 Gershater 2008 27 Gibbons 1995 43 Hering 2010 20 Hertzer 2007 63 Holstein 1989 64 Hughes 2004 65 Isaksson 2000 44 Jämsén 2002 66 Johnson 1995 67 Kabra 2013 38 Kalani 2013 40 
 
                   
 
 Are appropriate definitions included for the terms “ulcer”, “heali 1 1 1 0 0 1 1 0 1 0 0 0 0 0 0 0 0 
 
                    
 Was the choice of study population appropriate for the chosen 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0. 1   intervention and the stated conclusions?    
                   
 Was there a control population that was managed at the same 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   time as those in the intervention group or groups?    
                   
 Is the intervention sufficiently well described to enable another 
1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1   
researcher to replicate the study?  
                   
 Are the components of other aspects described for the 0 1 1 0 1 0 1 0 0 0 0 0 0 0 0 1 1   intervention and comparator groups?    
                   
Study Design Were the participants randomised into intervention and 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
comparator groups?    
                   
 Were the participants randomised by an independent person or 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   agency?    
                   
 Was the number of participants studied in the trial based on an 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   appropriate sample size calculation?    
                   
 Was the chosen primary outcome of direct clinical relevance?   1 0 0 0 1 1 0 1 1 0 0 0 1 0 0 0 0 
 
                   
 
 Was the person who assessed the primary outcome or 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   
outcomes blinded to group  allocation?                      
 
 Were either the clinical researcher who cared for the wound at 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   research visits or the participants blinded to group allocation?    
                   
 Did the study complete recruitment?   0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 
                    
 Was it possible to document the primary outcome in 75% or 
1 0 0 0 1 1 0 1 1 0 0 0 1 0 0 0 0   more of those recruited?    
                   
Study Conduct Were the results analysed primarily by ITT analysis?   0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0                     
Were appropriate statistical methods used throughout?   0 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1   
 
                    
 Was the performance in the control group of the order that 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   would be expected in routine clinical practice?    
                   
 Are the results from all participating centres comparable? 
0 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1   Answer “yes” if the study was done in only one centre.                    
 
 Is the report free from errors of reporting - e.g., discrepancies 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1   between data reported in different parts of the report?    
                   
 Are the important strengths and weaknesses of the study 
0 1 1 1 1 0 1 0 0 0 0 1 1 0 1 0 1   discussed in a balanced way?    
                   
Outcomes Are the conclusions supported by the findings?   1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 0 1 
 
                    
 Is the report free from any suggestion that the analysis or the                  
 
 conclusions could have  been substantially influenced by 
1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1   people with commercial or other personal interests in the                    
 
 findings?                    
 
 Study Design Case series Case series Cohort study Cohort study Case series Case series Cohort study Case series Case series Case series Cohort study Case series Case series Case series Case series Case series Cohort study 
 
                   
 
 Total Score (/21) 8 10 10 8 11 10 9 8 10 7 6 8 9 7 8 6 9 
 
                   
 
 
  
Domains Checklist Question Kalra 2001 68 Kandzari 2006 45 Leers 1998 69 Lejay 2013 70 Lewis 2010 52 Liu 2013 41 Malmstedt 2008 14 Mills 1994 71 Mohan 1996 72 Owen 2007 73 Panneton 2000 74 Parameswaran Park 2013 48 Pomposelli 1995 34 Pomposelli 2003 35 Premalatha 2002 50   
2005 51
 
 
                 
 
 Are appropriate definitions included for the terms “ulcer”, “heali 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 
                   
 Was the choice of study population appropriate for the chosen 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1   intervention and the stated conclusions?    
                  
 Was there a control population that was managed at the same 
0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0   time as those in the intervention group or groups?    
                  
 Is the intervention sufficiently well described to enable another 
1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1   
researcher to replicate the study?  
                  
 Are the components of other aspects described for the 0 0 0 0 0 1 0 0 0 0 0 0 0 1 1 0   intervention and comparator groups?    
                  
Study Design Were the participants randomised into intervention and 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
comparator groups?    
                  
 Were the participants randomised by an independent person or 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   agency?    
                  
 Was the number of participants studied in the trial based on an 
0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0   appropriate sample size calculation?    
                  
 Was the chosen primary outcome of direct clinical relevance?   0 1 0 0 0 0 1 0 0 0 0 0 1 0 0 0 
 
                  
 
 Was the person who assessed the primary outcome or 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   
outcomes blinded to group  allocation?                     
 
 Were either the clinical researcher who cared for the wound at 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   research visits or the participants blinded to group allocation?    
                  
 Did the study complete recruitment?   0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 
 
                   
 Was it possible to document the primary outcome in 75% or 
0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0   more of those recruited?    
                  
Study Conduct Were the results analysed primarily by ITT analysis?   0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0                    
Were appropriate statistical methods used throughout?   1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1   
 
                   
 Was the performance in the control group of the order that 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   would be expected in routine clinical practice?    
                  
 Are the results from all participating centres comparable? 1 0 1 1 0 1 0 1 1 1 1 1 1 1 1 1   Answer “yes” if the study was done in only one centre.                   
 
 Is the report free from errors of reporting - e.g., discrepancies 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1   between data reported in different parts of the report?    
                  
 Are the important strengths and weaknesses of the study 1 1 0 1 1 1 1 0 0 1 1 1 1 0 1 0   
discussed in a balanced way?                     
 
Outcomes Are the conclusions supported by the findings?   1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 
 
                   
 Is the report free from any suggestion that the analysis or the                 
 
 conclusions could have  been substantially influenced by 
1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1   
people with commercial or other personal interests in the                   
 
 findings?                   
 
 Study Design Case series Case series Case series Case series Cross-sectional Cross-sectional Cohort study Case series Case series Cohort study Case series Cross-sectional Case series Case series Case series Cross-sectional 
 
                  
 
 Total Score (/21) 8 10 5 7 8 8 11 7 7 8 8 8 9 8 9 7 
 
                  
 
 
  
Domains Checklist Question Pua 2008 75 Ramdev 2002 76 Reed 2002 77  Rigatelli 2011 78  Rosenbaum Saltzberg 2003 80 Schneider 1993 81 Schneider 2001 82 Sigala 2006 83 Soderstrom Söderström Stonebridge Tannenbaum Taylor 1987 37 Toursarkissian Toursarkissian  
1994 79
 
2008 84
 
2013 22 1991 85 1992 36 2002 (1) 86 2002 (2) 87             
 
 Are appropriate definitions included for the terms “ulcer”, “heali 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
 
                   
 Was the choice of study population appropriate for the chosen 
1 1 1 1 1 1 1 0 1 1 1 0 1 1 0 1   intervention and the stated conclusions?    
                  
 Was there a control population that was managed at the same 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   time as those in the intervention group or groups?    
                  
 Is the intervention sufficiently well described to enable another 
0 0 1 1 0 0 1 0 0 0 1 0 1 0 1 1   
researcher to replicate the study?  
                  
 Are the components of other aspects described for the 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0   intervention and comparator groups?    
                  
Study Design Were the participants randomised into intervention and 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0  
comparator groups?    
                  
 Were the participants randomised by an independent person or 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   agency?    
                  
 Was the number of participants studied in the trial based on an 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   appropriate sample size calculation?    
                  
 Was the chosen primary outcome of direct clinical relevance?   0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 
                  
 
 Was the person who assessed the primary outcome or 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   
outcomes blinded to group  allocation?                     
 
 Were either the clinical researcher who cared for the wound at 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   research visits or the participants blinded to group allocation?    
                  
 Did the study complete recruitment?   0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 
                   
 Was it possible to document the primary outcome in 75% or 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   more of those recruited?    
                  
Study Conduct Were the results analysed primarily by ITT analysis?   0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0                    
Were appropriate statistical methods used throughout?   1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1   
 
                   
 Was the performance in the control group of the order that 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   would be expected in routine clinical practice?    
                  
 Are the results from all participating centres comparable? 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1   Answer “yes” if the study was done in only one centre.                   
 
 Is the report free from errors of reporting - e.g., discrepancies 0 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1   between data reported in different parts of the report?    
                  
 Are the important strengths and weaknesses of the study 1 0 0 0 0 0 0 0 0 1 1 0 1 0 1 1   
discussed in a balanced way?                     
 
Outcomes Are the conclusions supported by the findings?   1 1 1 0 0 0 1 0 0 1 1 0 1 0 1 1 
 
                   
 Is the report free from any suggestion that the analysis or the                 
 
 conclusions could have  been substantially influenced by 
0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1   
people with commercial or other personal interests in the                   
 
 findings?                   
 
 Study Design Case series Case series Case series Case series Case series Case series Case series Cohort study Case series Case series Case series Case series Case series Case series Case series Case series 
 
                  
 
 Total Score (/21) 5 6 6 6 5 5 7 4 3 7 10 4 9 6 7 8 
 
                  
 
 
  
Domains Checklist Question Tsai 2013 28 Uccioli 2010 46 Verhelst 1997 88 Vogelberg 1988 55 Wallin 2013 89 Werneck 2009 47 Williams 2005 53 Woefle 2001 90 Woelfle 1993 91 Wolfle 2000 92 Zayed 2009 93 Zhan 2012 94 Zhang 2009 49 
 
               
 
 Are appropriate definitions included for the terms “ulcer”, “heali 1 0 0 0 0 0 0 0 0 0 0 0 0 
 
                
 Was the choice of study population appropriate for the chosen 
1 1 1 1 1 1 1 1 1 1 1 1 1   intervention and the stated conclusions?    
               
 Was there a control population that was managed at the same 
0 0 0 1 0 0 0 0 0 0 0 0 0   time as those in the intervention group or groups?    
               
 Is the intervention sufficiently well described to enable another 
1 1 0 1 1 1 1 1 0 1 0 1 1   
researcher to replicate the study?  
               
 Are the components of other aspects described for the 0 0 0 0 0 0 0 0 0 0 0 0 0   intervention and comparator groups?    
               
Study Design Were the participants randomised into intervention and 0 0 0 0 0 0 0 0 0 0 0 0 0  
comparator groups?    
               
 Were the participants randomised by an independent person or 
0 0 0 0 0 0 0 0 0 0 0 0 0   agency?    
               
 Was the number of participants studied in the trial based on an 
0 0 0 0 0 0 0 0 0 0 0 0 0   appropriate sample size calculation?    
               
 Was the chosen primary outcome of direct clinical relevance?   0 1 0 0 0 1 0 0 0 0 0 0 0 
 
               
 
 Was the person who assessed the primary outcome or 0 0 0 0 0 0 0 0 0 0 0 0 0   
outcomes blinded to group  allocation?                  
 
 Were either the clinical researcher who cared for the wound at 
0 0 0 0 0 0 0 0 0 0 0 0 0   research visits or the participants blinded to group allocation?    
               
 Did the study complete recruitment?   0 0 0 0 0 0 0 0 0 0 0 0 0 
 
                
 Was it possible to document the primary outcome in 75% or 
0 1 0 0 0 0 0 0 0 0 0 0 0   more of those recruited?    
               
Study Conduct Were the results analysed primarily by ITT analysis?   0 0 0 0 0 0 0 0 0 0 0 0 0                 
Were appropriate statistical methods used throughout?   1 1 1 1 1 1 1 1 1 1 0 1 1   
 
                
 Was the performance in the control group of the order that 
0 0 0 0 0 0 0 0 0 0 0 0 0   would be expected in routine clinical practice?    
               
 Are the results from all participating centres comparable? 1 1 1 1 1 1 1 1 1 1 1 1 1   Answer “yes” if the study was done in only one centre.                
 
 Is the report free from errors of reporting - e.g., discrepancies 1 1 0 1 1 1 1 1 1 1 1 1 1   between data reported in different parts of the report?    
               
 Are the important strengths and weaknesses of the study 1 1 0 0 0 1 0 0 0 0 0 1 1   
discussed in a balanced way?                  
 
Outcomes Are the conclusions supported by the findings?   1 1 0 0 1 0 1 1 0 1 1 1 1 
 
                
 Is the report free from any suggestion that the analysis or the              
 
 conclusions could have  been substantially influenced by 
1 1 1 1 1 1 1 1 1 1 1 1 1   
people with commercial or other personal interests in the                
 
 findings?                
 
 Study Design Cohort study Case series Case series Cross-sectional Cohort study Case series Cross-sectional Case series Case series Case series Case series Case series Case series 
 
               
 
 Total Score (/21) 9 10 4 7 7 8 7 7 5 7 5 8 8 
 
               
 
 
